Overview
Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.
Status:
Unknown status
Unknown status
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is being conducted to see if magnesium can reduce the number of shocks patients with ICDs experience and to see if magnesium supplementation improves patients quality of life.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Hartford Hospital
Criteria
Inclusion Criteria:newly implanted ICD or recent ICD shock (within 6 months) -Exclusion Criteria:inability to swallow, a non-cardiac disease with a survival prognosis of
less than 12 months, hypermagnesemia, a creatinine clearance less than 30mL/min, lactic
acidosis or systemic acidosis syndrome, or previous intolerance to magnesium L-lactate.
-